Kamada Ltd. Book Value 2011-2025 | KMDA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Kamada Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	319 M	179 M	135 M	112 M	89.5 M	66.7 M	72.5 M	80.4 M	90 M	28.4 M	22.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
319 M	22.7 M	109 M

Quarterly Book Value Kamada Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	319 M	217 M	-	-	211 M	206 M	-	-	174 M	-	-	-	138 M	-	-	-	122 M	-	-	-	99.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
319 M	99.7 M	186 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Cellectis S.A. CLLS	384 M	$ 4.3	12.57 %	$ 116 M	France
Graybug Vision GRAY	8.16 M	$ 0.44	-11.23 %	$ 9.65 M	USA
AgeX Therapeutics AGE	5.36 M	$ 11.3	-10.17 %	$ 12.2 K	-
Galera Therapeutics GRTX	-144 M	$ 0.14	-32.59 %	$ 7.61 M	USA
Cyclerion Therapeutics CYCN	9.58 M	$ 2.52	-1.18 %	$ 6.35 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	-9.4 M	$ 4.37	-1.58 %	$ 28.1 M	China
Caladrius Biosciences CLBS	29.3 M	$ 0.43	-16.75 %	$ 25.8 M	USA
Sorrento Therapeutics SRNE	78.1 M	$ 0.27	-29.58 %	$ 126 M	USA
BeiGene, Ltd. BGNE	3.33 B	$ 184.71	0.49 %	$ 251 B	Cayman-islands
Midatech Pharma plc MTP	8.32 M	$ 0.29	-18.52 %	$ 27.3 M	Britain
Aeterna Zentaris AEZS	13.2 M	$ 5.72	5.93 %	$ 314 M	Canada
ContraFect Corporation CFRX	-11.9 M	$ 1.47	-5.16 %	$ 5.39 M	USA
Orchard Therapeutics plc ORTX	98.3 M	$ 4.93	1.02 %	$ 90.8 M	Britain
Advaxis ADXS	16.6 M	$ 0.31	-9.65 %	$ 45.9 M	USA
Heat Biologics, Inc. HTBX	598 M	$ 3.93	-5.76 %	$ 99.8 M	USA
La Jolla Pharmaceutical Company LJPC	-66.7 M	$ 6.2	-	$ 154 M	USA
Zymeworks ZYME	249 M	$ 6.42	-	$ 404 M	Canada
Checkmate Pharmaceuticals CMPI	69.5 M	$ 10.5	-	$ 231 M	USA
Kadmon Holdings, Inc. KDMN	8.24 B	$ 9.5	-	$ 1.7 B	USA
BioDelivery Sciences International BDSI	188 M	$ 2.58	-4.8 %	$ 255 M	USA
Zosano Pharma Corporation ZSAN	33 M	$ 0.56	7.23 %	$ 2.72 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	$ 0.5	-	$ 7.46 M	Israel
Generation Bio Co. GBIO	203 M	$ 6.33	1.61 %	$ 408 M	USA
Kiromic BioPharma KRBP	-12.6 M	$ 3.15	6.61 %	$ 3.08 M	USA
Acceleron Pharma Inc. XLRN	362 M	$ 179.68	-	$ 10.9 B	USA
Albireo Pharma ALBO	176 M	$ 44.15	-0.23 %	$ 916 M	USA
Stealth BioTherapeutics Corp MITO	-45.3 M	$ 0.32	-	$ 23.9 M	USA
Trillium Therapeutics Inc. TRIL	-2.22 M	$ 18.44	-	$ 1.94 B	Canada
Kaleido Biosciences KLDO	10.6 M	$ 0.29	-3.69 %	$ 12.4 M	USA
Entasis Therapeutics Holdings ETTX	31.2 M	$ 2.19	-	$ 105 M	USA
Heron Therapeutics HRTX	-33.7 M	$ 1.35	2.27 %	$ 206 M	USA
ImmuCell Corporation ICCC	27.5 M	$ 6.59	2.17 %	$ 53.8 M	USA
Humanigen HGEN	-46.8 M	$ 0.04	-81.12 %	$ 4.28 M	USA
Aptinyx APTX	38.3 M	$ 0.06	-39.0 %	$ 4.57 M	USA
Tyme Technologies TYME	102 M	$ 0.31	8.07 %	$ 54 M	USA
Keros Therapeutics KROS	572 M	$ 15.96	1.98 %	$ 598 M	USA
Forward Pharma A/S FWP	71.4 M	$ 2.64	-0.75 %	$ 18.7 M	Danmark
Krystal Biotech KRYS	946 M	$ 187.18	2.27 %	$ 5.35 B	USA
Kymera Therapeutics KYMR	836 M	$ 56.29	-1.11 %	$ 4.22 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	$ 0.39	-	$ 26.5 M	USA
Celyad Oncology SA CYAD	79.9 M	$ 0.47	-	$ 12.5 M	Belgium
Brickell Biotech BBI	11.6 M	$ 2.11	-5.38 %	$ 6.06 M	USA
Genocea Biosciences GNCA	27.1 M	$ 0.05	-15.0 %	$ 3.04 M	USA
Codiak BioSciences CDAK	53.5 M	$ 0.06	-55.98 %	$ 2.15 M	USA
Concert Pharmaceuticals CNCE	112 M	$ 8.37	-	$ 401 M	USA
AIkido Pharma AIKI	39.9 M	$ 3.17	1.93 %	$ 17.4 M	USA
Calithera Biosciences CALA	49.1 M	$ 0.37	-10.95 %	$ 876 K	USA
Forma Therapeutics Holdings FMTX	498 M	$ 20.01	-	$ 958 M	USA
Arena Pharmaceuticals ARNA	785 M	$ 49.55	-6.81 %	$ 3.04 B	USA
Sierra Oncology SRRA	96 M	$ 54.89	-0.05 %	$ 1.34 B	Canada